# US 2019/0167659 A1 · Ccr6 compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167659 A1
- Document ID: US20190167659A1
- Status: Published application
- Kind: A1
- Application number: 16/150,796
- Filed: 2018-10-03
- Published: 2019-06-06
- Earliest claimed: 2013-12-02
- Assignees: ChemoCentryx, Inc.
- Applicants: Chemocentryx, Inc.
- Inventors: Daniel DAIRAGHI; Dean R. DRAGOLI; Jaroslaw KALISIAK; Christopher W. LANGE; Manmohan Reddy LELETI; Yandong LI; Rebecca M. LUI; Venkat Reddy MALI; Viengkham MALATHONG; Jay P. POWERS; Hiroko TANAKA; Joanne TAN; Matthew J. WALTERS; Ju YANG; Penglie ZHANG
- Web page: https://patentgrep.com/patent/US20190167659A1

## CPC

- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/16: for decreasing, blocking or antagonising the activity of the thyroid hormones
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 15/02: for disorders of the vagina
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 215/48: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/14: containing three or more hetero rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Compounds of formula (I) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:

## Claims

### Claim 1

A compound having formula (I):
or a pharmaceutically acceptable salt, hydrate, solvate, N-oxide or rotamer thereof,
wherein
A is a carboxylic acid moiety or a carboxylic acid isostere;
ring vertices a, b, c and d are independently selected from N, CH and C(R1);
each R1 is independently selected from the group consisting of halogen, CN, —SF5, C1-8 alkyl, C3-8 cycloalkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 haloalkyl, —ORa, —SRa, —CORa, —NRaRb, and 5- or 6-membered heteroaryl, wherein the alkyl portions of R1 are optionally further substituted with 1-3 Ra; and optionally, adjacent R1 members are connected to form an additional 5- or 6-membered ring which is saturated or unsaturated having ring vertices selected from C, O, S and N, wherein the additional 5- or 6-membered ring is optionally substituted with one or two members selected from the group consisting of halogen, hydroxyl, C1-4 alkyl, C1-4 alkoxy and C1-4 haloalkyl;
the subscript m is an integer of from 0 to 2;
the subscript n is an integer of from 0 to 3;
each R2 and R3 is independently selected from the group consisting of halogen, CN, C1-8 alkyl, C3-8 cycloalkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 haloalkyl, aryl, —ORa, —NRaRb and —N(Ra)—C1-C4 alkylene-ORb, and wherein the alkyl or aryl portions of R2 and R3 are optionally further substituted with 1-3 Ra;
Ar is a 5- or 6-membered aromatic or heteroaromatic ring that is optionally substituted with from 1 to 5 R4 substituents independently selected from the group consisting of halogen, CN, —SF5, C1-8 alkyl, C3-8 cycloalkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 haloalkyl, C1-8 hydroxyalkyl, —ORa, —NRaRb, 5- or 6-membered heteroaryl, and 3-, 4-, 5- or 6-membered heterocycloalkane wherein the heteroatoms present as ring vertices of the heteroaryl and heterocycloalkane rings are selected from N, O and S, and wherein the alkyl, cycloalkyl, aryl, heteroaryl and hetereocycloalkane portions of R4 are optionally further substituted with 1-3 Ra;
each Ra and Rb is independently selected from the group consisting of hydrogen, hydroxyl, halogen, cyano, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C3-6 cycloalkyl, amino, C1-8 alkylamino, and di C1-8 alkylamino, or when attached to a nitrogen atom are optionally combined to form a 4- to 7-membered saturated ring, which is optionally substituted with oxo.

### Claim at position 2

2-18. (canceled)

### Claim 19 (depends on 1)

A compound of claim 1, wherein Ar is selected from the group consisting of:
wherein the wavy line labeled w indicates the point of attachment to the S(O)2 moiety.

### Claim 20 (depends on 1)

A compound of claim 1, selected from the group consisting of:

### Claim 21 (depends on 1)

A compound of claim 1, selected from the group consisting of:
or a pharmaceutically acceptable salt, hydrate, solvate, N-oxide or rotamer thereof.

### Claim 22 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, N-oxide or rotamer thereof, with a pharmaceutically acceptable excipient.

### Claim 23 (depends on 1)

A method of treating a disease or condition modulated at least in part by CCR6, comprising administering to a subject in need thereof, a compound of claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, N-oxide or rotamer thereof.

### Claim 24 (depends on 23)

A method in accordance with claim 23, wherein said disease or condition is an inflammatory disease or condition.

### Claim 25 (depends on 23)

A method in accordance with claim 23, wherein said disease or condition is atopic dermatitis.

### Claim 26 (depends on 23)

A method in accordance with claim 23, wherein said disease or condition is psoriasis.

### Claim 27 (depends on 19)

A method of treating a disease or condition modulated at least in part by CCR6, comprising administering to a subject in need thereof, a compound of claim 19, or a pharmaceutically acceptable salt, hydrate, solvate, N-oxide or rotamer thereof.

### Claim 28 (depends on 27)

A method in accordance with claim 27, wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt, hydrate, solvate, N-oxide or rotamer thereof.

### Claim 29 (depends on 27)

A method in accordance with claim 27, wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt, hydrate, solvate, N-oxide or rotamer thereof.